Clareo Health | Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
This study will include a retrospective and prospective observational database analysis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age greater than or equal to18 years;
First allogeneic HCT for cHL;
Patients with prior autologous HCT for cHL;
Any conditioning regimen, graft source or donor type.
For the primary analysis additional criterion includes prior exposure to nivolumab for treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used alone or in combination with other agents and used as the last line of therapy prior to an allogeneic HCT with the interval between the last dose of nivolumab and start of the conditioning regimen no longer than 12 months.
You may not be if
Patients with nodular lymphocyte-predominant HL
Previous chimeric antigen receptor T-cell therapy or other genetically modified cellular product
